Latest News

Roche gets FDA priority review for atezolizumab

PD-L1 (programmed death-ligand 1), which is expressed on tumour cells and tumour-infiltrating immune cells, interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, atezolizumab can trigger activation of T cells, restoring their ability to effectively detect and attack tumour cells. © Genentech


by tg

Roche is expanding its indications in cancer immunotherapy. Following FDA approvals of its PD-L1 checkpoint inhibitor atezolizumab in NSCLC and bladder cancer patients refractive to platinum-based chemotherapy, the Swiss pharma major is awaiting a FDA decision on whether the antibody is suitable as first-line treatment in a further subpopulation of bladder cancer patients.

Based on results of a single arm Phase II study, the FDA granted atezolizumab Priority Review in an additional type of advanced bladder cancer. While the agency granted accelerated market approval in May 2016 for the anti-PD-L1 antibody in patients who were treatment-refractive to platinum-based chemotherapy in neoadjuvant or adjuvant setting, the current priority review extends treatment options. Until April 2017, the agency will decide on the approval of atezolizumab in patients with bladder cancer not eligible for cisplatin chemotherapy (first-line treatment) or disease progression after 12 months of cisplatin therapy before or after surgery.

Roche’s supplemental biologics license application (sBLA) submission for atezolizumab is based on results from the Phase II IMvigor210 study. IMvigor210 is an open-label, single-arm Phase II study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic bladder cancer, regardless of PD-L1 expression. The primary endpoint of the study was objective response rate (ORR). Secondary endpoints included duration of response (DOR), overall survival (OS), progression-free survival (PFS) and safety.

Calcium does not contribute to heart failure

In animal models, the group headed by Karl Toischer from University of Göttingen, showed that pharmacological decrease of calcium leak from...

British F2G Biotech bags €24m

F2G Biotech said it will be spending most of the assets to push forward pivotal clinical trials of its lead compound Olorofim (F901318), a Phase IIb...

PD1/PD-L1blockers trigger metastases

A retrospective study on 377 patients with advanced non small cell lung cancer (NSCLC) who received PD-1 blockers as second-line therapy or later...

Takeda strikes US$640m deal with Enterome

Takeda will pay US$50 upfront for a global licence of EB8018, Enterome's lead bacterial inflammation blocker, targeting Crohn’s disease, that...

EU set to speed up switch to bioeconomy by new action plan

Research Commissioner Carlos Moedas said in Brussels that much has been achieved in the past six years since the EC established the bioeconomy...

Phase III success for Roche breast cancer drug

Roche said the phase III study KATHERINE met its primary endpoint, showing Kadcyla (trastuzumab emtansine) as a single agent significantly reduced...

Antibiotic resistance spreading across Europe

A new Lancet report based on data the EARS-Net provided in 2015 counts 33,000 deaths due to AMR, 39% thereof caused by infections with...